Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors

The clinical efficacy and durability of KRAS<sup>G12C</sup>-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRAS<sup>G12C</sup>-targeted therapy and immunotherapy-unifying strategies that utilize covalently modif...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Abdel Mouti, M, Pauklin, S
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: Cell Press 2023